On Feb. 21, 2025, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has determined the shortage of Wegovy^® and Ozempic^® is resolved. The FDA’s assessment confirms the U.S. supply of these prescription-only GLP-1 medicines now meets or exceeds both current and projected U.S. demand.

The company continues to operate production facilities 24 hours a day, seven days a week with all doses of Wegovy^® and Ozempic^® being shipped regularly to wholesalers. This update comes after ongoing dialogue with the FDA, and substantial efforts by Novo Nordisk to increase manufacturing capacity, including $6.5 billion dollars of investments in the U.S. this year alone.

The FDA’s decision also means that making or selling a knockoff compounded drug that is essentially a copy of Ozempic or Wegovy is illegal, under compounding laws, with rare exceptions.